基于肌酐和胱抑素C的GFR估算方程监测中度慢性肾病的准确性:前瞻性纵向队列研究
该前瞻性纵向队列研究纳入1229例中度慢性肾病成人,评估含肌酐和胱抑素C的GFR估算方程在三年内监测GFR变化的准确性。结果显示双生物标志物方程与实测GFR变化的一致性优于单肌酐方程,但所有方程检测疾病进展的敏感性均较低。
要点
- 双生物标志物GFR方程监测变化优于单肌酐方程
- 所有方程检测肾病进展敏感性低于54.1%
- 估算方程可能低估GFR下降幅度,需进一步研究
核心结论
- 含肌酐和胱抑素C的方程比单生物标志物方程更准确地监测实测GFR变化。
- 估算GFR低估了实测GFR的下降幅度,需进一步研究。
- 所有方程识别慢性肾病进展的敏感性低但特异性好。
研究设计与样本
- 前瞻性纵向队列研究,2014年4月1日至2017年12月31日在英格兰六个中心开展。
- 纳入1229例≥18岁中度慢性肾病成人,基线肌酐估算GFR为30-59 mL/min/1.73 m2持续至少三个月。
- 最终875例参与者有基线和三年时的实测与估算GFR数据,构成研究队列。
主要发现
- 三年后实测GFR中位数从48.1 mL/min/1.73 m2降至43.6 mL/min/1.73 m2。
- 所有方程中实测GFR变化中位数均超过估算GFR变化中位数。
- 所有方程与实测GFR变化的一致性均超过72.5%的参与者。
- 双生物标志物方程一致性:CKD-EPIcreatinine-cystatin为78.6%(95%CI 75.8%至81.3%),CKD-EPI(2021)creatinine-cystatin为78.1%(75.2%至80.8%),EKFCcreatinine-cystatin为80.2%(77.4%至82.8%),均优于CKD-EPIcreatinine的73.1%(70.1%至76.1%),所有P<0.001。
- 139例(15.9%)个体出现肾病进展;所有方程识别进展的敏感性<54.1%,特异性>90.4%。
关键数值与推荐
- 一致性定义为估算方程与实测GFR变化斜率偏差在±3 mL/min/1.73 m2/年内。
- 疾病进展定义为实测GFR降低≥25%且疾病分期下降。
临床怎么用
- 临床实践中增加使用联合生物标志物方程可能改善疾病监测。
- 需注意估算方程可能低估GFR下降,且对进展识别敏感性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To provide evidence on the longitudinal accuracy of glomerular filtration rate (GFR) estimating equations that include creatinine and cystatin C to monitor patients with moderate chronic kidney disease. DESIGN: Prospective, longitudinal, cohort study. SETTING: Primary, secondary, and tertiary care across six centres in England, 1 April 2014 to 31 December 2017. PARTICIPANTS: 1229 adults (≥18 years) with moderate chronic kidney disease (creatinine estimated GFR of 30-59 mL/min/1.73 m2 for at least three successive months before recruitment). MAIN OUTCOME MEASURES: Ability of estimating equations to monitor GFR over three years, with slope deviations from reference measured GFR (iohexol clearance) within ±3 mL/min/1.73 m2/year indicating agreement. Ability of GFR estimating equations to detect disease progression (ie, a reduction in measured GFR of ≥25% with a reduction in disease category). RESULTS: After three years, 875 participants had measured and estimated GFR data recorded at the start and end of the study and comprised the study cohort. Median measured GFR decreased from 48.1 mL/min/1.73 m2 at baseline to 43.6 mL/min/1.73 m2 at three years. GFR was estimated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and European Kidney Function Consortium (EKFC) estimating equations. Median change in measured GFR exceeded median change in estimated GFR for all equations. All equations achieved agreement with change in measured GFR in >72.5% of participants. Dual biomarker equations showed better agreement with change in measured GFR (CKD-EPIcreatinine-cystatin 78.6% of individuals, 95% confidence interval 75.8% to 81.3%; CKD-EPI(2021)creatinine-cystatin 78.1%, 75.2% to 80.8%; and EKFCcreatinine-cystatin 80.2%, 77.4% to 82.8%) than CKD-EPIcreatinine (73.1%, 70.1% to 76.1%) (all P<0.001). Progression of kidney disease was seen in 139 (15.9%) individuals. All GFR equations had poor sensitivity (<54.1%) but good specificity (>90.4%) for identifying progression of chronic kidney disease. CONCLUSIONS: Underestimation of the reduction in GFR by estimated GFR requires further investigation. Equations that included both creatinine and cystatin C more accurately monitored change in measured GFR than equations based on one biomarker. Increased use of combined biomarker equations in clinical practice could improve disease monitoring and potentially clinical care. STUDY REGISTRATION: ISRCTN registry ISRCTN42955626.
引用
- Scandrett K, Sitch AJ, Barratt J, et al. Accuracy of glomerular filtration rate estimation based on creatinine and cystatin C for monitoring moderate chronic kidney disease in adults: prospective, longitudinal cohort study. BMJ. 2026. PMID: 41856526. doi:10.1136/bmj-2025-085005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。